EPO and neoplasm: Drawing inspiration from the erythropoietin (EPO) biosynthetic process, an EPO enhancer has been constructed to impart the EPO-Keap1 plasmid (DNA) with tumor hypoxia-activated functionality, disrupting the redox homeostasis of the TME.